Fresenius Medical Care's Stake in Humacyte Diluted to 6.8% Following Recent Public Offering
HUMA sits 98% above its 52-week low of $0.547 on light trading volume (0.1× avg).
Summary
Fresenius Medical Care's ownership stake in Humacyte has been diluted to 6.8% as a result of Humacyte's recent $50 million public offering, with no shares sold by Fresenius.
Key Events · Ownership and Investor Activity · HUMA
-
Beneficial Ownership Reduced
Fresenius Medical Care's reported beneficial ownership in Humacyte, Inc. has decreased from 8.4% to 6.8% of outstanding common stock.
-
Dilution, Not Sale
The decrease in percentage ownership is attributed solely to an increase in Humacyte's total outstanding shares, specifically from the recent $50 million public offering, and not from any disposition of shares by Fresenius Medical Care.
-
Impact of Recent Offering
The filing confirms the dilutive effect of Humacyte's $50 million public offering, priced on June 10, 2026, on a major existing shareholder's stake.
Analysis · HUMA · Life Sciences
This Schedule 13D/A filing confirms that Fresenius Medical Care's beneficial ownership in Humacyte has decreased from 8.4% to 6.8%. This reduction is solely due to the increase in Humacyte's outstanding shares from its recent $50 million public offering, not from any sales by Fresenius. The filing highlights the dilutive impact of Humacyte's capital raising activities on existing significant shareholders.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 28.9% of the 1476 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HUMA was trading at $1.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $240.9M. The 52-week trading range was $0.55 to $2.84. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.